Browse Category:

Categories

[Search within category]

Monoclonal Antibody against ATR-IP (Clone 11)

Mouse monoclonal antibody against the human ATR-interacting protein (ATR-IP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against CEP164 (Clone 13)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against CEP164 (Clone 17)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunoprecipitation and western blot.

Monoclonal Antibodies Against Chk2 (Clone 4B8)

Mouse monoclonal antibody (clone 4B8) against the human Serine/threonine-protein kinase Chk2. This antibody has been tested for use in immunoprecipitation and western blot.

Monoclonal Antibodies Against Mtpap (Clone 1D3)

Mouse monoclonal antibody against the human Poly (A) RNA polymerase, mitochondrial (mtPAP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Cyclic Amp-Elevating Drugs As Adjuvants - 2014-084

Effective adjuvants enhance antigen immunogenicity and/or modulate the type of immunity (e.g., humoral vs. cellular immune response), and, in theory, an optimal antigen-adjuvant combination should activate the both arms of the immune system (innate and adaptive immunity). Different adjuvants work via different mechanisms and, ultimately, the best adjuvant for any specific vaccine will be chosen on the basis of compatibility with the delivery route (e.g., systemic vs. mucosal), ability to provoke the desired immune response (e.g., humoral vs. cellular immunity), and relevance to a particular stage of the required anti-microbial protection (e.g., preventive vs. therapeutic immunity). One way to achieve these diverse goals is to use a combination of complementary, synergistic adjuvants and this is one current practice. However, an adjuvant that could trigger the immunomodulatory cascade upstream of current options could simplify the design of safe and effective vaccines and revolutionize modern day vaccinations.

NOVEL GLIOMA-SPECIFIC VACCINE FOR PEDIATRIC AND YOUNG-ADULT PATIENTS

UCSF researchers have developed a vaccine against pediatric gliomas by targeting a novel epitope.  

Monoclonal Antibody Against mtPAP (Clone 3D2)

Mouse monoclonal antibody against the human Poly (A) RNA polymerase, mitochondrial (mtPAP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot. .

Monoclonal Antibody Against PNPase (Clone 3H5)

Mouse monoclonal antibody against the human mitochondrial polyribonucleotide nucleotidyltransferase 1 (PNPase). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Erodible Polymer Particle Oral Vaccine Adjuvant

Brief description not available

Novel Agonists of Toll-like Receptors (TLRs) for Cancer Immunotherapy and Vaccination

Toll-like receptors are part of the innate immune system, which is a widely-deployed and evolutionarily conserved means of defending against pathogens. And, although cancer cells are notoriously adept at evading the immune system, UC researchers have identified novel TLR agonists that use innate immunity to target tumor cells and provide immunotherapeutic options. The approach is validated by the potent anti-tumor activity of such compounds as imiquimod and resiquimod but these drugs are limited by inherent short half-lives and there is a distinct need for compounds with increased efficacy at these proven targets.

Novel Agonists of Toll-like Receptors (TLRs) for Infectious Disease and Vaccination

Toll-like receptors (TLRs) are a set of conserved cellular proteins that play an important role in the recognition of microbial pathogens and in initiating the first line of host innate immune response. Although early work suggested that modulating the response could have clinical utility, few agents have been able to clear regulatory hurdles to development and TLR-7 agonists have been challenged by side-effects of cardiotoxicity and myelosuppression.

High-Throughput Profiling of Point Mutations across the HIV-1 Genome

The Sun Group at UCLA has developed a quantitative, high-throughput assessment of the mutational susceptibility of genomic regions of HIV-1 to aid drug design.

A Vaccine-Like Treatment That Protects Honey Bees Against Nosema

Managed honey bee colonies are responsible for the pollination of over $20 billion in US crops, but are suffering major declines due to multiple factors, including disease.  Nosema ceranae, a small, unicellular parasite, causes a major honey bee disease, nosemosis, which infects approximately 70% of managed honey bee colonies in the USA.  It is also a major disease in multiple countries around the world.  The primary effective treatment against Nosema is the antibiotic, fumagillin.  Some studies have suggested the use of natural oils and other treatments, but none have proved as highly effective as fumagillin.  However, N. ceranae is evidently becoming more resistant to fumagillin.  Current usage of fumagillin may actually exacerbate N. ceranae infections.  A treatment that boosts natural honey bee immunity would thus be highly beneficial since N. ceranae will inevitably become more resistant to fumagillin over time.

Modulation of in utero Immune Programming

The in utero environment is an important determinant of potential disease. In particular, epidemiological evidence links dysmetabolic conditions during pregnancy with atherosclerosis, diabetes and hypertension later in life, which then leads to a wave of cardiovascular disease in the offspring. It has further been demonstrated that maternal hypercholesterolemia is one of the causes of developmental programming of atherosclerosis and is associated with increased fatty streak formation in human fetal arteries and accelerated progression of atherosclerosis during normocholesterolemic childhood.

Immunogenic Peptides as Vaccines against Herpes Simplex Virus

Immunogenic peptides isolated from HSV seropositive asymptomatic (ASYMP) individuals induce a CD8+ T cell- dependent protective immunity against herpes virus in a mammal.

Automated Chemoenzymatic Synthesis Of Glycans And Glyconconjugates

Providers of research tools have manufactured and synthesized peptides, proteins, and DNA inexpensively for the scientific community; and yet the synthesis of carbohydrates has yet to be automated or streamlined. Researchers at the University of California, Davis have developed a novel method to automate the synthesis of glycans and glycoconjugates.

Heterodimer of Toll-Like Receptor Agonists for Cancer Immunotherapy

TLR agonists, such as CpG, have been used as immunotherapies against tumors in clinical studies. TLR agonists promote tumor-specific Th1 and cytotoxic T lymphocyte responses that allows the immune system to develop responses to eradicate tumors. Researchers at the University of California, Irvine have developed a heterodimer consisting of lipoteichoic acid (LTA), a TLR2 agonist, and CpG, a TLR 9 agonist, conjugated by a PEG linker. This novel heterodimer greatly enhances Th1 response and elicits the highest activation of dendritic cells and macrophages unlike unconjugated LTA or CpG.

Identification of Major Cashew and Walnut Allergens

Cashews and walnuts are commonly used in snack foods and as an ingredient in a veriety of processed foods, such as bakery and confectionary products. For those who are allergic to those nuts, consuming them can lead to reactions ranging from dermatitis to deadly anaphylactic shock. Researchers at the University of California, Davis in conjunction with Florida State University have identified specific amino acid sequences in walnut and cashew proteins that produce allergic reactions in humans.

Titanium Dioxide (TiO2) Photocatalysts for Water Purification

More and more chemicals of various origins are being discharged into our local water streams, ending up at waste and water treatment facilities.  These chemicals comprising of pharmaceuticals, personal care products, and other various industrial chemicals are currently not removed by typical wastewater treatment practices.  Further, current regulations from the Food and Drug Administration do not require testing or removing these chemicals even as their amounts aggregate in our drinking water.  Therefore, the general public is currently being exposed to these dangerous chemicals that pose significant adverse health risks.                          

Live Recombinant Tuberculosis Vaccine

Brief description not available

Small Molecule, TLR-4 Ligands as Immunomodulators

As part of a comprehensive campaign to screen for effective vaccine adjuvants, 180,000 compounds were tested in a cell-based HTS screen to assess ability to activate NF-kB. Several classes of scaffolds bearing appropriate substitutions were found to stimulate innate immune responses and some of these scaffolds were structurally different from all other known ligands. More interestingly, the structure of one class of scaffolds challenges current dogma regarding what is necessary for efficacy.

Novel Inactivated Virus Vaccine Against Herpesviruses

Herpes simplex virus type 2 (HSV-2) infection is the most common cause of genital herpes, a sexually transmitted disease estimated to affect more than 500 million people worldwide. About one in six people in the United States aged between 14 and 49 years has genital herpes caused by HSV-2. In addition to causing painful recurring genital sores and emotional stress in those infected, the disease can be particularly severe in immunosuppressed patients and can cause death or brain damage in babies born to infected mothers. Antiviral drugs are being used widely to treat HSV-2, but they are ineffective at eradicating the disease. There is therefore an urgent need for a safe and effective HSV-2 vaccine.

Novel Viral Vaccine Design Methodology

Attenuated, or weakened, viruses have played a significant role in the development of vaccines, such as the current vaccine for tuberculosis. Viruses undergo genetic change through mutation and recombination of their genetic material, the result of which may be either an increase in pathogenicity or the initiation of an immune response within the host organism. For example, point mutations have been used in the development of attenuated viruses for respiratory vaccines to allow for greater phenotypic stability of the viral vaccine. Current vaccines are typically systemic in nature and are not targeted to a specific tissue within the body. The development of a tissue-specific vaccine could hold significant promise in the development of new treatments for cancers or for the generation of targeted immunity.   Viruses also play an important role in the developing field of gene therapy. Viruses have been used to introduce and target replacement gene sequences to specific tissues to replace defective ones. Viruses are uniquely suited to this as they naturally infect host cells and integrate their genetic material with that of the host cell.

  • Go to Page:

University of California
Innovation Alliances and Services

1111 Franklin Street, 5th Floor,Oakland,CA 94607-5200 |
http://www.ucop.edu/ott/
Tel: 510.587.6000 | Fax: 510.587.6090 | UC.technologies@ucop.edu